Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 10/20 | 0.50 |
| ▸ | CTSK | P43235 | 9/20 | 0.50 |
| ▸ | CTSL | P07711 | 2/20 | 0.48 |
| ▸ | CTSB | P07858 | 2/20 | 0.48 |
| ▸ | PPARA | Q07869 | 6/20 | 0.45 |
| ▸ | PPARG | P37231 | 5/20 | 0.45 |
| ▸ | ACE | P12821 | 1/20 | 0.44 |
| ▸ | PPARD | Q03181 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL755894 | 1.00 | CTSS (0.50) | CTSSCTSKCTSLCTSBPPARA | |
| SCHEMBL939477 | 1.00 | CTSS (0.50) | CTSSCTSKCTSLCTSBPPARA | |
| SCHEMBL7330819 | 0.91 | CTSK (0.44) | CTSSCTSKCTSLCTSBPPARA | |
| SCHEMBL15582702 | 0.87 | CTSS (0.48) | CTSSCTSKCTSLCTSBCA1 | |
| SCHEMBL1688920 | 0.87 | CTSK (0.47) | CTSSCTSKCTSLCTSBCA1 | |
| SCHEMBL3735030 | 0.87 | CTSK (0.47) | CTSSCTSKCTSLCTSBCA1 | |
| SCHEMBL12973256 | 0.87 | CTSK (0.47) | CTSSCTSKCTSLCTSBCA1 | |
| SCHEMBL3733285 | 0.87 | CTSK (0.47) | CTSSCTSKCTSLCTSBCA1 | |
| SCHEMBL16000767 | 0.87 | CTSK (0.47) | CTSSCTSKCTSLCTSBCA1 | |
| SCHEMBL16343552 | 0.86 | CTSK (0.46) | CTSSCTSKCTSLCTSBPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 398 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112778162-B | Preparation method of chiral beta- (Boc-amino) -5-hexynoic acid | 上海海皋科技有限公司 | 2023-06-16 | — | — | CN | claimed |
| CN-115850338-A | Compound containing diazirine nucleosides as well as preparation method and application thereof | 西安交通大学 | 2023-03-28 | — | — | CN | claimed |
| CN-112778162-A | Preparation method of chiral beta- (Boc-amino) -5-hexynoic acid | 上海海皋科技有限公司 | 2021-05-11 | — | — | CN | claimed |
| CN-110407749-B | Photoaffinity linker containing disulfide bond, preparation method and application thereof | 西安交通大学 | 2021-01-19 | — | — | CN | claimed |
| CN-110483398-B | Photoaffinity linker containing biodegradable group, preparation method and application thereof | 西安交通大学 | 2020-11-10 | — | — | CN | claimed |
| US-20260116857-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOFS | PARDES BIOSCIENCES INC (US) | 2026-04-30 | — | — | US | disclosed |
| EP-3897833-B1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMA (US) | 2026-02-04 | — | — | EP | disclosed |
| EP-3681875-B1 | CYCLIC PEPTIDE ANTIBIOTICS | HOFFMANN LA ROCHE (CH) | 2026-01-14 | — | — | EP | disclosed |
| US-20250042878-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMA (US) | 2025-02-06 | — | — | US | disclosed |
| US-12145911-B2 | Inhibitors of cysteine proteases and methods of use thereof | Pardes Biosciences, Inc. (US) | 2024-11-19 | — | — | US | disclosed |
| US-20240270693-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. (US) | 2024-08-15 | — | — | US | disclosed |
| US-20240270721-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2024-08-15 | — | — | US | disclosed |
| US-5252591-A | Renin inhibitors | G. D. SEARLE & COMPANY | 1993-10-12 | — | — | US | disclosed |
| US-5246969-A | Oligopeptides as renin inhibitors | G. D. SEARLE & CO. (US) | 1993-09-21 | — | — | US | disclosed |
| US-5227401-A | ETHYNYL ALANINE AMINO DIOL COMPOUNDS FOR TREATMENT OF HYPERTENSION | G. D. SEARLE & CO. (US) | 1993-07-13 | — | — | US | disclosed |
| US-5223535-A | Renin inhibitors | G. D. SEARLE & CO. (US) | 1993-06-29 | — | — | US | disclosed |
| US-5212185-A | Enzyme inhibitors | G. D. SEARLE & CO. (US) | 1993-05-18 | — | — | US | disclosed |
| WO-1993009086-A1 | PROPARGYL GLYCINE AMINO PROPARGYL DIOL COMPOUNDS FOR TREATMENT OF HYPERTENSION | G.D. SEARLE & CO. (US) | 1993-05-13 | — | — | WO | disclosed |
| WO-1993009087-A1 | ETHYNYL ALANINE AMINO DIOL COMPOUNDS FOR TREATMENT OF HYPERTENSION | G.D. SEARLE & CO. (US) | 1993-05-13 | — | — | WO | disclosed |
| EP-0539976-A1 | Ethynyl-alanine-amino-diol compounds for treatment of hypertension | G.D. Searle & Co. (US) | 1993-05-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260116857-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOFS | CTRC, CTRL, CTSL | CTSS 7/4885CTSK 50/4885CTSL 3/4885 |
| US-20250042878-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | APOL1, APOB, SAAL1 | CTSS 342/4885CTSK 200/4885CTSL 68/4885 |
| US-20240270693-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTRL, CTSV, CTSL | CTSS 7/4885CTSK 43/4885CTSL 3/4885 |
| US-20240270721-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTSV, CTRL, CTSL | CTSS 10/4885CTSK 49/4885CTSL 3/4885 |
| US-12145911-B2 | Inhibitors of cysteine proteases and methods of use thereof | CTRL, CTSV, CTSL | CTSS 7/4885CTSK 43/4885CTSL 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.